FinnGen provides genetic insights from a well-phenotyped isolated population

Mitja Kurki(Broad Institute), Juha Karjalainen(Broad Institute), Priit Palta(University of Helsinki), Timo P. Sipilä(University of Helsinki), Kati Kristiansson(Finnish Institute for Health and Welfare), Kati Donner(University of Helsinki), Mary Pat Reeve(University of Helsinki), Hannele Laivuori(University of Helsinki), Mervi Aavikko(University of Helsinki), Mari Kaunisto(University of Helsinki), Anu Loukola(University of Helsinki), Elisa Lahtela(University of Helsinki), Hannele Mattsson(Finnish Institute for Health and Welfare), Päivi Laiho(Finnish Institute for Health and Welfare), Pietro Della Briotta Parolo(University of Helsinki), Arto Lehistö(University of Helsinki), Masahiro Kanai(Broad Institute), Nina Mars(University of Helsinki), Joel Rämö(University of Helsinki), Tuomo Kiiskinen(University of Helsinki), Henrike Heyne(Broad Institute), Kumar Veerapen(Broad Institute), Sina Rüeger(University of Helsinki), Susanna Lemmelä(University of Helsinki), Wei Zhou(Broad Institute), Sanni Ruotsalainen(University of Helsinki), Kalle Pärn(University of Helsinki), Tero Hiekkalinna(Finnish Institute for Health and Welfare), Sami Koskelainen(Finnish Institute for Health and Welfare), Teemu Paajanen(Finnish Institute for Health and Welfare), Vincent Llorens(University of Helsinki), Javier Gracia‐Tabuenca(Tampere University), Harri Siirtola(Tampere University), Kadri Reis(University of Tartu), Abdelrahman G. Elnahas(University of Tartu), Benjamin B. Sun(Biogen (United States)), Christopher N. Foley(University of Cambridge), Katriina Aalto‐Setälä(Tampere University), Kaur Alasoo(University of Tartu), Mikko Arvas(Finnish Red Cross), Kirsi Auro(Glaxosmithkline (Finland)), Shameek Biswas(Bristol-Myers Squibb (United States)), Argyro Bizaki-Vallaskangas(Tampere University Hospital), Olli Carpén(University of Helsinki), Chia‐Yen Chen(Biogen (United States)), Oluwaseun Alexander Dada(University of Helsinki), Zhihao Ding(Boehringer Ingelheim (Germany)), Margaret G. Ehm(GlaxoSmithKline (United States)), Kari K. Eklund(Helsinki University Hospital), Martti Färkkilâ(University of Helsinki), Hilary K. Finucane(Broad Institute), Andrea Ganna(Broad Institute), Awaisa Ghazal(University of Helsinki), Robert Graham(Maze (United States)), Eric M. Green(Maze (United States)), Antti Hakanen(University of Turku), Marco Hautalahti, Åsa K. Hedman(Pfizer (United States)), Mikko Hiltunen(Tampere University), Reetta Hinttala(Oulu University Hospital), Iiris Hovatta(University of Helsinki), Xinli Hu(Pfizer (United States)), Adriana Huertas‐Vázquez(Merck & Co., Inc., Rahway, NJ, USA (United States)), Laura Huilaja(Oulu University Hospital), Julie Hunkapiller, Howard J. Jacob(AbbVie (United States)), Jan-Nygaard Jensen(Boehringer Ingelheim (Germany)), Heikki Joensuu(University of Helsinki), Sally John(Biogen (United States)), Valtteri Julkunen(University of Eastern Finland), Marc Jung(Boehringer Ingelheim (Germany)), Juhani Junttila(Borealis (Finland)), Kai Kaarniranta(University of Eastern Finland), Mika Kähönen(Tampere University), Risto Kajanne(University of Helsinki), Lila Kallio(University of Turku), Reetta Kälviäinen(University of Eastern Finland), Jaakko Kaprio(University of Helsinki), FinnGen(University of Tartu), Nurlan Kerimov(Finnish Institute for Health and Welfare), Johannes Kettunen(University of Helsinki), Elina Kilpeläinen(University of Helsinki), Terhi Kilpi(Finnish Institute for Health and Welfare), K. Klinger(University of Eastern Finland), Veli‐Matti Kosma(University of Eastern Finland), Teijo Kuopio(Tampere University of Applied Sciences), Venla Kurra(Tampere University of Applied Sciences), Triin Laisk(University of Eastern Finland), Jari A. Laukkanen(Boehringer Ingelheim (Germany)), Nathan Lawless(Boehringer Ingelheim (Germany)), Aoxing Liu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Simonne Longerich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Reedik Mägi(University of Tartu), Johanna Mäkelä(University of Helsinki), Antti Mäkitie(University of Helsinki), Anders Mälarstig(University of Eastern Finland), Arto Mannermaa(University of Eastern Finland), Joseph Maranville(AstraZeneca (United Kingdom)), Athena Matakidou(AstraZeneca (United Kingdom)), Tuomo J Meretoja(University of Helsinki), Sahar V. Mozaffari(University of Helsinki), Mari Niemi(University of Helsinki), Marianna Niemi(University of Helsinki), Teemu Niiranen(University of Turku), Christopher J. O´Donnell(Novartis (United States)), Ma´en Obeidat(Boehringer Ingelheim (Germany)), George Okafo(Boehringer Ingelheim (Germany)), Hanna M. Ollila(University of Helsinki), Antti Palomäki(University of Helsinki), Tuula Palotie(University of Helsinki), Jukka Partanen(AstraZeneca (United Kingdom)), Dirk S. Paul(AstraZeneca (United Kingdom)), Margit Pelkonen(Kuopio University Hospital), Rion Pendergrass(AstraZeneca (United Kingdom)), Slavé Petrovski(AstraZeneca (United Kingdom)), Anne Pitkäranta(AstraZeneca (United Kingdom)), Adam Platt(AstraZeneca (United Kingdom)), David Pulford(University of Helsinki), Eero Punkka(University of Helsinki), Pirkko J. Pussinen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Neha Raghavan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fedik Rahimov(AbbVie (United States)), Deepak K. Rajpal(Novartis (United States)), Nicole Renaud(AbbVie (United States)), Bridget Riley‐Gillis(University of Helsinki), Rodosthenis S. Rodosthenous(University of Helsinki), Elmo Saarentaus(University of Helsinki), Aino Salminen(University of Helsinki), Eveliina Salminen(University of Helsinki), Veikko Salomaa(University of Turku), Johanna Schleutker(University of Turku), Raisa Serpi(University of Helsinki), Huei-Yi Shen(Novartis (Switzerland)), Richard W. Siegel(Novartis (Switzerland)), Kaisa Silander(Tampere University), Sanna Siltanen(Tampere University), Sirpa Soini(University of Eastern Finland), Hilkka Soininen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jae Hoon Sul(AstraZeneca (United Kingdom)), Ioanna Tachmazidou(AstraZeneca (United Kingdom)), Kaisa Tasanen(University of Helsinki), Pentti Tienari(University of Helsinki), Sanna Toppila‐Salmi(University of Helsinki), Taru Tukiainen(University of Helsinki), Tiinamaija Tuomi(University of Helsinki), Joni A. Turunen(Broad Institute), Jacob C. Ulirsch(Broad Institute), Felix Vaura(University of Turku), Petri Virolainen(University of Turku), Jeffrey F. Waring(AbbVie (United States)), Dawn Waterworth(Janssen (Belgium)), Robert Yang(Janssen (Belgium)), Mari Nelis(University of Tartu), Anu Reigo(University of Tartu), Andres Metspalu(University of Tartu), Lili Milani(University of Tartu), Tõnu Esko(Merck & Co., Inc., Rahway, NJ, USA (United States)), Caroline S. Fox(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aki S. Havulinna(University of Helsinki), Markus Perola(University of Helsinki), Samuli Ripatti(University of Helsinki), Anu Jalanko(University of Helsinki), Tarja Laitinen(University of Helsinki), Tomi P. Mäkelä(University of Helsinki), Robert M. Plenge(Bristol-Myers Squibb (United States)), Mark I. McCarthy(Biogen (United States)), Heiko Runz(Broad Institute), Mark J. Daly(Broad Institute), Aarno Palotie(Broad Institute)
Nature
January 18, 2023
Cited by 4,031Open Access
Full Text

Abstract

Abstract Population isolates such as those in Finland benefit genetic research because deleterious alleles are often concentrated on a small number of low-frequency variants (0.1% ≤ minor allele frequency < 5%). These variants survived the founding bottleneck rather than being distributed over a large number of ultrarare variants. Although this effect is well established in Mendelian genetics, its value in common disease genetics is less explored 1,2 . FinnGen aims to study the genome and national health register data of 500,000 Finnish individuals. Given the relatively high median age of participants (63 years) and the substantial fraction of hospital-based recruitment, FinnGen is enriched for disease end points. Here we analyse data from 224,737 participants from FinnGen and study 15 diseases that have previously been investigated in large genome-wide association studies (GWASs). We also include meta-analyses of biobank data from Estonia and the United Kingdom. We identified 30 new associations, primarily low-frequency variants, enriched in the Finnish population. A GWAS of 1,932 diseases also identified 2,733 genome-wide significant associations (893 phenome-wide significant (PWS), P < 2.6 × 10 –11 ) at 2,496 (771 PWS) independent loci with 807 (247 PWS) end points. Among these, fine-mapping implicated 148 (73 PWS) coding variants associated with 83 (42 PWS) end points. Moreover, 91 (47 PWS) had an allele frequency of <5% in non-Finnish European individuals, of which 62 (32 PWS) were enriched by more than twofold in Finland. These findings demonstrate the power of bottlenecked populations to find entry points into the biology of common diseases through low-frequency, high impact variants.


Related Papers

No related papers found

Powered by citation graph analysis